Cresset Asset Management LLC Has $784,000 Stake in Edwards Lifesciences Corporation $EW

Key Points

• Cresset Asset Management LLC reduced its position in Edwards Lifesciences Corporation by 39.0%, now holding 10,817 shares worth $784,000 after selling 6,913 shares during the 1st quarter.
• Insider selling activity included VP Donald E. Bobo, Jr. selling 2,570 shares and insider Larry L. Wood selling 8,950 shares, indicating a decrease in their ownership of the stock.
• Wall Street analysts have shown optimism with a mix of ratings; three analysts rated the stock as a Strong Buy, while the consensus rating is a "Moderate Buy" with a price target of $85.90.

Cresset Asset Management LLC lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 39.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,817 shares of the medical research company's stock after selling 6,913 shares during the quarter. Cresset Asset Management LLC's holdings in Edwards Lifesciences were worth $784,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in EW. American Century Companies Inc. lifted its stake in Edwards Lifesciences by 9.3% in the first quarter. American Century Companies Inc. now owns 1,274,184 shares of the medical research company's stock valued at $92,353,000 after buying an additional 108,127 shares during the last quarter. Ethic Inc. lifted its stake in Edwards Lifesciences by 39.1% in the first quarter. Ethic Inc. now owns 56,168 shares of the medical research company's stock valued at $4,037,000 after buying an additional 15,775 shares during the last quarter. Sector Gamma AS lifted its stake in Edwards Lifesciences by 24.2% in the first quarter. Sector Gamma AS now owns 123,000 shares of the medical research company's stock valued at $8,915,000 after buying an additional 24,000 shares during the last quarter. Element Capital Management LLC bought a new stake in Edwards Lifesciences in the first quarter valued at $2,781,000. Finally, Dimensional Fund Advisors LP lifted its stake in Edwards Lifesciences by 6.7% in the first quarter. Dimensional Fund Advisors LP now owns 3,196,992 shares of the medical research company's stock valued at $231,676,000 after buying an additional 201,784 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.9090 during trading hours on Monday, reaching $80.9210. 4,393,047 shares of the company were exchanged, compared to its average volume of 4,195,043. The firm has a market cap of $47.51 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 3.95 and a beta of 1.08. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average of $77.58 and a 200 day moving average of $74.72. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a research report on Tuesday, July 29th. Finally, Stifel Nicolaus boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $85.90.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president owned 50,356 shares of the company's stock, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,584 shares of company stock worth $1,897,762 over the last three months. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.